Novel Approaches to New Therapies for Hepatitis B Virus Infection
Novel Approaches to New Therapies for Hepatitis B Virus Infection
复制标题
DOI：
10.1177/135965350601100113
复制
发表时间：
2006-01
影响因子：
1.2
通讯作者：
R. Loomba;T. Liang
中科院分区：
文献类型：
--
作者：
R. Loomba;T. Liang
乙肝是世界上最流行的病毒性疾病之一。它会在10%的感染者中导致慢性肝病，使他们面临与肝脏相关的发病率和肝硬变和肝细胞癌并发症死亡率的增加风险。尽管在许多国家普遍接种乙肝疫苗取得了成功，但这种疾病仍然是一个主要的公共卫生问题，每年导致50多万人死亡。尽管目前治疗慢性乙型肝炎(CHB)的方法是有效的，但它并不是最理想的；需要新的方法来管理CHB。对病毒-宿主相互作用的更深入的了解，基因治疗的进展，针对乙肝病毒生命周期不同阶段的分子治疗的发展，以及对各种免疫调节方法的新见解，将导致开发更好的治疗药物来管理慢性乙肝。这些进展预示着联合治疗的新时代即将到来。在这篇综述中，我们将讨论新出现的治疗方法和潜在的机制，并强调这些新的治疗策略的前景和陷阱。
Hepatitis B is one of the most prevalent viral diseases in the world. It leads to chronic liver disease in 10% of infected individuals, putting them at an increased risk for liver-related morbidity and mortality from complications of cirrhosis and hepatocellular carcinoma. Despite the success of universal hepatitis B vaccination in many countries, this disease remains a major public health problem, resulting in more than 500,000 deaths per year. Although the current therapy for chronic hepatitis B (CHB) is effective, it is not optimal; novel approaches to the management of CHB are needed. An improved understanding of virus-host interactions, advances in gene therapy, the development of molecular therapies targeted at different stages of the hepatitis B virus life cycle, and new insights into various approaches of immune modulation will lead to the development of better therapeutic agents for the management of CHB. These advances herald a new era of combination therapy. In this review, we will discuss emerging therapies and potential mechanisms, and highlight the promises and pitfalls of these new treatment strategies.